126 related articles for article (PubMed ID: 22389470)
1. HER2 as therapeutic target for overcoming ATP-binding cassette transporter-mediated chemoresistance in small cell lung cancer.
Minami T; Kijima T; Otani Y; Kohmo S; Takahashi R; Nagatomo I; Hirata H; Suzuki M; Inoue K; Takeda Y; Kida H; Tachibana I; Kumanogoh A
Mol Cancer Ther; 2012 Apr; 11(4):830-41. PubMed ID: 22389470
[TBL] [Abstract][Full Text] [Related]
2. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
[TBL] [Abstract][Full Text] [Related]
3. Trastuzumab emtansine suppresses the growth of HER2-positive small-cell lung cancer in preclinical models.
Morimura O; Minami T; Kijima T; Koyama S; Otsuka T; Kinehara Y; Osa A; Higashiguchi M; Miyake K; Nagatomo I; Hirata H; Iwahori K; Takimoto T; Takeda Y; Kida H; Kumanogoh A
Biochem Biophys Res Commun; 2017 Jul; 488(4):596-602. PubMed ID: 28526406
[TBL] [Abstract][Full Text] [Related]
4. Inhibitors of ABCB1 and ABCG2 overcame resistance to topoisomerase inhibitors in small cell lung cancer.
Omori M; Noro R; Seike M; Matsuda K; Hirao M; Fukuizumi A; Takano N; Miyanaga A; Gemma A
Thorac Cancer; 2022 Aug; 13(15):2142-2151. PubMed ID: 35719112
[TBL] [Abstract][Full Text] [Related]
5. Human ATP-Binding Cassette transporters ABCB1 and ABCG2 confer resistance to CUDC-101, a multi-acting inhibitor of histone deacetylase, epidermal growth factor receptor and human epidermal growth factor receptor 2.
Wu CP; Hsiao SH; Su CY; Luo SY; Li YQ; Huang YH; Hsieh CH; Huang CW
Biochem Pharmacol; 2014 Dec; 92(4):567-76. PubMed ID: 25450670
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy-Regulated microRNA-125-HER2 Pathway as a Novel Therapeutic Target for Trastuzumab-Mediated Cellular Cytotoxicity in Small Cell Lung Cancer.
Yagishita S; Fujita Y; Kitazono S; Ko R; Nakadate Y; Sawada T; Kitamura Y; Shimoyama T; Maeda Y; Takahashi F; Takahashi K; Tamura T; Koizumi F
Mol Cancer Ther; 2015 Jun; 14(6):1414-23. PubMed ID: 25833836
[TBL] [Abstract][Full Text] [Related]
7. HER2 targeting near-infrared photoimmunotherapy for a CDDP-resistant small-cell lung cancer.
Takahashi K; Taki S; Yasui H; Nishinaga Y; Isobe Y; Matsui T; Shimizu M; Koike C; Sato K
Cancer Med; 2021 Dec; 10(24):8808-8819. PubMed ID: 34729945
[TBL] [Abstract][Full Text] [Related]
8. Role of efflux pump activity in lapatinib/caelyx combination in breast cancer cell lines.
Vannini I; Zoli W; Fabbri F; Ulivi P; Tesei A; Carloni S; Brigliadori G; Amadori D
Anticancer Drugs; 2009 Nov; 20(10):918-25. PubMed ID: 19752719
[TBL] [Abstract][Full Text] [Related]
9. Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.
Hu J; Zhang X; Wang F; Wang X; Yang K; Xu M; To KK; Li Q; Fu L
Oncotarget; 2015 Dec; 6(42):44643-59. PubMed ID: 26556876
[TBL] [Abstract][Full Text] [Related]
10. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS
Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847
[TBL] [Abstract][Full Text] [Related]
11. Overcoming chemoresistance of small-cell lung cancer through stepwise HER2-targeted antibody-dependent cell-mediated cytotoxicity and VEGF-targeted antiangiogenesis.
Minami T; Kijima T; Kohmo S; Arase H; Otani Y; Nagatomo I; Takahashi R; Miyake K; Higashiguchi M; Morimura O; Ihara S; Tsujino K; Hirata H; Inoue K; Takeda Y; Kida H; Tachibana I; Kumanogoh A
Sci Rep; 2013; 3():2669. PubMed ID: 24036898
[TBL] [Abstract][Full Text] [Related]
12. GW583340 and GW2974, human EGFR and HER-2 inhibitors, reverse ABCG2- and ABCB1-mediated drug resistance.
Sodani K; Tiwari AK; Singh S; Patel A; Xiao ZJ; Chen JJ; Sun YL; Talele TT; Chen ZS
Biochem Pharmacol; 2012 Jun; 83(12):1613-22. PubMed ID: 22414725
[TBL] [Abstract][Full Text] [Related]
13. Combination of SN-38 with gefitinib or imatinib overcomes SN-38-resistant small-cell lung cancer cells.
Takigawa N; Takeyama M; Kozuki T; Shibayama T; Hisamoto A; Kiura K; Tada A; Hotta K; Umemura S; Ohashi K; Fujiwara Y; Takata S; Ichihara E; Osawa M; Tabata M; Tanimoto M; Takahashi K
Oncol Rep; 2007 May; 17(5):983-7. PubMed ID: 17390033
[TBL] [Abstract][Full Text] [Related]
14. Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib.
Gilmer TM; Cable L; Alligood K; Rusnak D; Spehar G; Gallagher KT; Woldu E; Carter HL; Truesdale AT; Shewchuk L; Wood ER
Cancer Res; 2008 Jan; 68(2):571-9. PubMed ID: 18199554
[TBL] [Abstract][Full Text] [Related]
15. Favorable response to trastuzumab plus irinotecan combination therapy in two patients with HER2-positive relapsed small-cell lung cancer.
Kinehara Y; Minami T; Kijima T; Hoshino S; Morimura O; Otsuka T; Hayama Y; Fukushima K; Takeuchi Y; Higashiguchi M; Miyake K; Hirata H; Nagatomo I; Inoue K; Takeda Y; Kida H; Kumanogoh A
Lung Cancer; 2015 Mar; 87(3):321-5. PubMed ID: 25601188
[TBL] [Abstract][Full Text] [Related]
16. Lapatinib antagonizes multidrug resistance-associated protein 1-mediated multidrug resistance by inhibiting its transport function.
Ma SL; Hu YP; Wang F; Huang ZC; Chen YF; Wang XK; Fu LW
Mol Med; 2014 Sep; 20(1):390-9. PubMed ID: 25105301
[TBL] [Abstract][Full Text] [Related]
17. Lapatinib.
Voigtlaender M; Schneider-Merck T; Trepel M
Recent Results Cancer Res; 2018; 211():19-44. PubMed ID: 30069757
[TBL] [Abstract][Full Text] [Related]
18. Enhancing chemosensitivity in ABCB1- and ABCG2-overexpressing cells and cancer stem-like cells by an Aurora kinase inhibitor CCT129202.
Cheng C; Liu ZG; Zhang H; Xie JD; Chen XG; Zhao XQ; Wang F; Liang YJ; Chen LK; Singh S; Chen JJ; Talele TT; Chen ZS; Zhong FT; Fu LW
Mol Pharm; 2012 Jul; 9(7):1971-82. PubMed ID: 22632055
[TBL] [Abstract][Full Text] [Related]
19. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
Nakamura Y; Oka M; Soda H; Shiozawa K; Yoshikawa M; Itoh A; Ikegami Y; Tsurutani J; Nakatomi K; Kitazaki T; Doi S; Yoshida H; Kohno S
Cancer Res; 2005 Feb; 65(4):1541-6. PubMed ID: 15735043
[TBL] [Abstract][Full Text] [Related]
20. Pelitinib (EKB-569) targets the up-regulation of ABCB1 and ABCG2 induced by hyperthermia to eradicate lung cancer.
To KK; Poon DC; Wei Y; Wang F; Lin G; Fu L
Br J Pharmacol; 2015 Aug; 172(16):4089-106. PubMed ID: 25988710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
